Drug intelligence / Profile preview

MVP-105

Development stage: Preclinical
Lead developer: Multiverse Pharma
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

MVP-105 is a preclinical-stage blood-brain barrier (BBB) shuttle being developed by Multiverse Pharma. It is designed to target the insulin-like growth factor 1 receptor (IGF-1R) to facilitate the transport of therapeutic payloads across the BBB via receptor-mediated transcytosis. This technology aims to enable the delivery of large molecules and other targeted therapies into the central nervous system, addressing a major challenge in treating neurological disorders by overcoming the physiological barriers that typically limit drug penetration into the brain.

Targets

IGF-1R (Insulin-like growth factor 1 receptor)

Beyond the preview

Go deeper on MVP-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP-105.

Explore the full profile